Delorme M A, Inwood M J, O'Keefe B
Division of Hematology and Oncology, St. Joseph's Health Centre, University of Western Ontario, London, Canada.
Clin Lab Haematol. 1990;12(4):433-6. doi: 10.1111/j.1365-2257.1990.tb00355.x.
The thrombin clotting time (TCT) has been used at our institution, along with the activated partial thromboplastin time (aPTT), for monitoring heparin therapy. We have observed that, in some patients, a discrepancy develops between the heparin levels predicted by the TCT and the aPTT with the TCT consistently predicting a lower heparin level than the aPTT. An inverse relationship was noted between the functional antithrombin III (AT-III) level and the magnitude of this discrepancy.